VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
SANA
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
SANASana Biotechnology, Inc.
$1.85$515M
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
HomeStocksSANACash Flow

Sana Biotechnology, Inc. (SANA) Cash Flow Statement

8Y historyFree accessUpdated daily

Operating cash flow was negative in all ten reported quarters, with free cash flow ranging from negative $71.6 million in 2024Q2 to negative $39.5 million in 2026Q3, and capital expenditures remaining minimal, indicating the burn tracks operating losses.

Income StatementBalance SheetCash FlowRatios

SANA Cash Flow Statement

Annual statement

SANA Cash Flow Statement

Sana Biotechnology, Inc. (SANA) cash flow statement — 8-year operating, investing & financing cash flows

AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18
Cash from Operations-141.56M-143.83M-223.15M-253.58M-290.05M-251.05M-137.98M-85.5M-13.49M
Operating CF Margin %---------
Operating CF Growth %23.23%35.55%12%12.57%-15.53%-81.95%-61.37%-533.6%-
Net Income-149.27M-244.17M-266.76M-283.25M-269.48M-355.93M-285.31M-130.78M-13.25M
Depreciation & Amortization15.71M12.75M15.5M24.56M15.63M11.07M5.92M1.83M1K
Stock-Based Compensation22.67M25.46M37.68M35.53M38.34M22.36M5.83M1.5M118K
Deferred Taxes0000000-7.55M0
Other Non-Cash Items-22.84M72.24M-8.39M-49.03M-82.08M61.64M129.42M38.97M-228K
Working Capital Changes-7.83M-10.11M-1.19M18.61M7.54M9.8M6.16M10.53M-308K
Change in Receivables000000000
Change in Inventory000000000
Change in Payables-35K-3.54M1.38M1.03M1.06M-266K1.98M-421K289K
Cash from Investing-32.23M-40.24M17.45M172.01M210.56M-245.8M-252.56M-87.86M-780K
Capital Expenditures-3.57M-938K-33.43M-20.03M-20.88M-29.86M-23.87M-26.18M-460K
CapEx % of Revenue---------
Acquisitions883K1.43M0-192.04K-231.44K00-3.19M0
Investments---------
Other Investing94K00192.04K231.44K-4.57M059K-320K
Cash from Financing111.1M128.73M199.75M31.65M4.91M631.75M435.69M223.73M45.72M
Debt Issued (Net)-182K-347K188.74M000000
Equity Issued (Net)111.47M129.08M192M31.65M4.91M631.75M435.54M223.74M45.72M
Dividends Paid000000000
Share Repurchases000000000
Other Financing-184K0-181M000149K-14K0
Net Change in Cash-62.69M-55.33M-5.95M-49.92M-74.58M134.9M45.14M50.36M31.45M
Free Cash Flow-145.13M-144.77M-256.58M-273.61M-310.93M-280.92M-161.85M-111.69M-13.96M
FCF Margin %---------
FCF Growth %8.63%43.58%6.22%12%-10.68%-73.56%-44.92%-700.34%-
FCF per Share-0.47-0.57-1.11-1.41-1.65-1.69-0.86-0.60-0.07
FCF Conversion (FCF/Net Income)0.97x0.59x0.84x0.90x1.08x0.71x0.48x0.65x1.02x
Interest Paid000000000
Taxes Paid000000000

Key Metrics

Growth RegimeMixed
ProfitabilityNegative
Balance SheetStrained
Cash FlowBurning
Top Statement Risk

Cash runway constraint, dilution risk

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q3)

Operating Cash Burn Persists Despite Swings

Based on reported figures, Sana's operating cash flow stayed negative in every one of the ten reported quarters, with OCF/NI ratios of 0.35 to 1.16 indicating the cash drain tracks operating losses rather than non-cash noise.

The OCF-to-net-income ratio is not meaningful in quarters with positive net income, such as 2026Q3, where a $20.4 million profit coexisted with a $38.8 million operating cash outflow, suggesting the earnings turn is driven by non-operating or non-cash items. Across the period, operating cash outflows of roughly $30 million to $58 million per quarter align closely with reported losses, which implies that the stock-based compensation add-back of about $5 to $11 million per quarter is not what is masking the burn. Investors should treat the 2026Q3 profit as a potential accounting artifact and monitor whether future quarters reconcile net income with operating cash flow.

Free Cash Flow Deficit Narrowing Unevenly

As reported in financial statements, Sana's free cash flow ranged from negative $71.6 million in 2024Q2 to negative $33.0 million in 2025Q2, with the most recent quarter at negative $39.5 million reflecting a reversal of the earlier narrowing trend.

Free cash flow has no revenue denominator, so the FCF margin is unavailable, and the trajectory must be read in absolute dollars, where the burn has oscillated rather than declined steadily. The 2026Q3 deterioration to negative $39.5 million, after several quarters in the $33 million to $38 million range, suggests spending pressure is re-accelerating as clinical programs advance. This pattern warrants attention because a sustained burn rate near $35 million to $40 million per quarter implies a runway measured in a small number of quarters against the reported $71.87 million cash balance.

Minimal Capital Intensity Limits Asset Drag

According to recent SEC filings, Sana's capital expenditures remained small, ranging from a $112,000 inflow to a $13.1 million outflow, which indicates the company is not building fixed-asset capacity at scale.

Capex/revenue cannot be computed because revenue is absent, but the dollar figures show that the bulk of the 2024Q2 $13.1 million outlay was a one-time facility or equipment commitment rather than a recurring maintenance requirement. Since capex averaged well under $1 million in most recent quarters while D&A ran between $2 million and $8 million, the depreciation base is likely dominated by previously acquired lab assets and intangibles. This suggests near-term capex is unlikely to be the primary driver of cash consumption, which remains tied to R&D operating spend.

Working Capital Swings Mask Underlying Burn

Based on Sana's reported figures, working capital changes ranged from a $10.9 million drain in 2025Q1 to a $4.3 million inflow in 2024Q4, a volatility large enough to shift quarterly cash burn by a meaningful share.

The alternating sign of working capital movements, including a $6.5 million outflow in 2026Q1 followed by a $1.5 million inflow in 2026Q2, suggests timing differences in accrued clinical and payable balances rather than a structural shift in collections or payment terms. Because there is no revenue receivable base, the swings most likely reflect accrual timing on research contracts, which may reverse and therefore should not be extrapolated. Analysts should avoid treating favorable quarters as evidence of improving efficiency given the absence of a receivables cycle to interpret.

Runway Risk Obscured by Loss Narrowing

Based on reported figures, Sana's $71.87 million cash position against quarterly operating outflows frequently exceeding $30 million suggests the balance covers only a few quarters, which may force dilutive financing before clinical milestones are reached.

The positive 2026Q3 net income could be read as improvement, yet the same quarter shows a $38.8 million operating outflow and a $39.5 million free cash deficit, so the earnings figure does not reflect liquidity generation. Cash reserves are not augmented by operations, and the reported Debt/Equity of 0.49 provides limited offset to the pressure of needing new equity or partnership capital. The cash flow data does not disclose committed financing or non-dilutive funding, so these outcomes warrant further investigation rather than being assumed.

SANA — Frequently Asked Questions

Quick answers to the most common questions about buying SANA stock.

How much cash does Sana Biotechnology, Inc. (SANA) generate from operations?

Sana Biotechnology, Inc. (SANA) generated $-143.8M in net cash from operating activities in 2025. This reflects the cash generated directly from core business operations.

What is Sana Biotechnology, Inc.'s free cash flow?

Sana Biotechnology, Inc. (SANA) reported negative free cash flow of $144.8M in 2025, indicating capital requirements exceeded cash from operations.

What is Sana Biotechnology, Inc.'s capital expenditure (CapEx)?

Sana Biotechnology, Inc. (SANA) spent $0.9M on capital expenditures in 2025. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.